Argent Biopharma Limited has released a press release.
MGC Pharma Signs Agreement Targeting Anti-Viral Treatments
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- MGC Pharma COVID-19 Business and Operations Update
- Patients Begin Treatment in Clinical Trial of CogniCann
- Binding Amendment to Supply Agreement with ONIX Brazil
- Commercial Supply Deal Signed for First Products into Poland
- 85% Increase in Order Volume of New Prescription Products
Later from Argent Biopharma
- Pause In Trade
- Phase II Clinical Trial on Patients Diagnosed with COVID-19
- Successful Research Results for MGC on Glioblastoma
- MGC Pharma Secures Commitments for $3.5m Placement
- Second Ethics Committee Approval for Phase II COVID-19 Trial
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma